Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
This is a multicenter study to evaluate if the effectiveness of desvenlafaxine succinate sustained-release tablet (50 mg/day) used for 8 weeks is not inferior to duloxetine hydrochloride enteric-coated capsule (60 mg/day) in adult patients with major depressive disorder. A total of 400 subjects will be randomly allocated to experimental arm (desvenlafaxine succinate sustained-release tablet) and active comparator arm (duloxetine hydrochloride enteric-coated capsule) in a 1:1 ratio.
Age
18–65
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
18 ≤ age ≤ 65 years old, male or female;
Outpatients and inpatients who met the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR) criteria and Neuropsychiatric Interview5.0.0 (MINI5.0.0) for a primary diagnosis of Major Depressive Disorder(MDD), single or recurrent episode and measured by the Mini-International Neuropsychiatric Interview5.0.0 (MINI5.0.0) as active stage.
Hamilton Psychiatric Rating Scale for Depression (HAM-D17) total score of \>= 18.
You may not be if
Hamilton Rating Scale for Anxiety (HAM-A) total score of \> 14.
Refractory depression: Ineffective after adequate treatment with two or more antidepressants.
Current or previous diagnosis of Axis I with DSM-IV other than depression.
Significant risk of suicide based on clinical judgment or HAM-D 17, Suicide attempt in the past 6 months.
Any unstable hepatic, renal, pulmonary, cardiovascular (including uncontrolled hypertension), ophthalmologic, neurologic, or any other medical condition that might confound the study or put the subject at greater risk during study participation.
Clareo Health | Study of Desvenlafaxine in Treating Major Depressive Disorder.
